Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rapamycin-insensitive companion of mTOR (RICTOR) is an essential, defining subunit of the mechanistic target of rapamycin complex 2 (mTORC2). Unlike mTORC1, mTORC2 is insensitive to acute rapamycin treatment and plays a distinct role in regulating cell survival, proliferation, metabolism, and cytoskeletal organization. RICTOR acts as a critical scaffold protein within mTORC2, facilitating the phosphorylation and activation of AGC kinase family members, most notably AKT at Ser473, which is a key step for full AKT activation. Aberrant activation of RICTOR, frequently driven by RICTOR gene amplification or protein overexpression, is implicated in various malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, and glioblastoma, where it promotes tumor growth, metastasis, and resistance to therapy. Consequently, RICTOR and the mTORC2 complex have emerged as attractive therapeutic targets. While direct, selective inhibitors of RICTOR are primarily in preclinical development (such as JR-AB2-011, which disrupts the Rictor-mTOR interaction), dual mTORC1/2 inhibitors like vistusertib and sapanisertinib have been evaluated in clinical trials for patients with RICTOR-amplified solid tumors.
mTORC1/mTORC2 dual inhibition, mTORC2-specific inhibition, and disruption of Rictor-mTOR protein-protein interaction
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rapamycin-insensitive companion of mTOR (RICTOR) (RICTOR).